

BG SALES-TRADING MORNING DU 02/08/2016

LA SEANCE DE LA VEILLE									
INDICES U.S & JAPON				SECTEURS S&P : BEST PERFS			SECTEURS STOXX : BEST PERFS		
Indices	Cloture	Var %	Var 17h30-22H (en %)	S&P	Var %	YTD	STOXX	Var %	YTD
DJ	18404,5	-0,2%	-0,1%	Tech Hardware	1,2	5,4	Healthcare	0,2	-2,9
NASDAQ	5184,2	0,4%	0,2%	PHARMA.	1	2,9	Basic Resources	0,2	30,3
S&P 500	2170,8	-0,1%	-0,1%	Household Products	0,9	8,6	Real Estate	-0,1	-1,4
NIKKEI	16417,5	-1,3%	-	Real Estate	0,5	12,4	Telecom	-0,1	-13,4
SECTEURS S&P : WORST PERFS.					SECTEURS STOXX : WORST PERFS				
				S&P	Var %	YTD	STOXX	Var %	YTD
				Oil & Gaz	-3,3	8,3	Oil & Gas	-1,8	4,3
				Telecom Op.	-1	20,7	Banks	-1,8	-28,4
				Auto	-0,8	-6,7	Financial Serv.	-1	-13,4
				Banks	-0,7	-9,7	Const. & Materials	-0,8	0,1

Valeurs les plus traitées hier vs. Moy. 3M									
CAC 40			EURO STOXX 50			STOXX 600			
Stocks*	Last	Var%	Stocks*	Last	Var %	Stock*s	Last	Var%	
LEGRAND SA	51,2	3,8	INTESA SANPAOLO	1,9	-3,5	JUST EAT PLC	534	-0,6	
KERING	172,2	1,4	CARREFOUR SA	22,2	-0,9	ASM INTERNATIONAL	33,4	-4,3	
CARREFOUR SA	22,2	-0,9	SAFRAN SA	62	2	PEARSON PLC	882,5	0,1	
SAFRAN SA	62	2	UNICREDIT SPA	2	-9,4	LOGITECH	19,4	-1,3	
ENGIE	14,4	-2,2	ENGIE	14,4	-2,2	CASINO GUICHARD	45,9	-5,2	

DEFINITION : * compare les capitaux traités sur une valeur la veille rapportés à la moyenne des capitaux traités ces 3 derniers mois sur la valeur.

TAUX U.S				DEVICES				MAT. PREMIERES			
Taux U.S	Valeur	Var%	Yld	Devises	Valeur	Var%	YTD	Mat. Prem	Valeur	Var%	YTD
U.S 2 ANS	100,1	0%	0,7%	€//\$	1,1181	0,2%	2,9%	BRENT	40,8	0%	14,2%
U.S 10 ANS	101	0,1%	1,5%	€/¥	114,2	0,1%	14,4 %	ONCE OR (\$)	1351,9	-0,1%	27,4%

VIX Index	12,4	4,8%	VSTOXX Index	20,3	0,4%
-----------	------	------	--------------	------	------

Economic Calendar

GB - Markit Construction PMI Jul . (44 E, 46 P)

US - Personal income Jun. (0.3% E)

US - Personal consumption exp. (1.6% E)

Dividends Calendar ex-date next day

Ex Div today

REMY COINTREAU	1.6€ (2.1%)
OENEO (SABT.PA)	0.13€ (1.57%)

Markets Recap (source Street account)

Asian markets are narrowly mixed in quiet Tuesday trade. Oil's latest sell-off has to led energy sector underperformance. The Nikkei is trading water ahead an expected announcement by Prime Minister Abe detailing his fiscal stimulus program. Reports continue to highlight the potential for a ~¥28T package, of which ~¥7T is earmarked for direct expenditure.

Greater Chinese markets are flat, where morning trade on the Hang Seng has been interrupted by a typhoon. The government's crackdown on the poorly regulated fund management sector continued with Asset Management Association of China (AMAC) shutting down 10,000 funds. The economic calendar is headlined by the RBA, which is expected to lower the cash rate by 25 bp to 1.50%. The decision is due in 30 minutes time. Other data showed the Aussie trade deficit widened while building approvals contracted.

US equities were mixed in quiet trading on Monday. Treasuries were weaker with some curve steepening. The dollar was higher with the DXY +0.24%. Gold +0.2% was modestly higher. Oil was under substantial pressure again with WTI (3.7%).

Other than the oil selloff, the session was quiet. Despite a number of economic releases, there was

limited impact on the growth narrative. July ISM manufacturing was slightly weaker than expected. July manufacturing PMIs were mixed. June construction spending was worse than expected. European bank stress tests from late Friday were in focus, but there were no real surprises. Monetary policy also received attention as the Fed's Dudley warned that the futures market was too complacent about potential rate increases. Overall, however, his comments were considered dovish in part due to his view that it would be worse for the Fed to hike too soon than to move too late.

Sectors were mixed. Healthcare +0.59% and tech +0.40% were the best performers. Energy (3.33%) was the worst performer on crude weakness.

Stocks Factor to watch today :

FRESENIUS SE: Guidance 2016 Raised, net income is now expected to grow by 11% to 14% in CER (8% to 12% previously). Q2 Sales €7.1bn (+2%, +5% at CER), EBIT €1.05bn, Net income €393m

FRESENIUS MC : confirmed guidance after Q2 results, Sales \$4,42m, Ebit \$641m, \$294m.

INTERCONTINENTAL : H1 underlying profit rose 2.1% to 344m USD, Q2 REVPAR up 2.5% with growth in all regions. Remain confident in outlook for remainder of year. Expects Foreign exchange to have an impact on 2016 reported profit.

METRO : reported unexpected quarterly loss on restructuring costs. Q3 EBIT before items 154m EURO (€182m cns), Q3 Sales down 2.7% to €13.6bn vs. cns 13.8, CEO says demerger plans on track

STOXX 50 : ASML & VINCI will be added to Stoxx 50, CREDIT SUISSE and DEUTSCHE BANK will be removed

Rating & TP Changes



VEOLIA : TP raised to €23.5 vs. 23, BUY @ Bryan Garnier

DANONE : added to Europe Super Ten @HSBC

TOTAL : added to Europe Super Ten @HSBC

WORLDPAY : TP raised to 350p, BUY @Goldman Sachs

VINCI : TP raised to €83, BUY @ Goldman Sachs

ASTRAZENECA : TP raised to 4815p vs. 4240 @HSBC

DIAGEO : TP raise to 2350p vs. 2100 @HSBC

UCB : TP raised to €77 vs. 76 @Berenberg

HEINEKEN : TP raised to €90 vs. 88 @JPM



GRIFOLS TP cut TO €23 vs. 24, BUY @ UBS

Technical Analysis

HIGHEST YTD : ADIDAS, ASTRAZENECA, CARLSBERG, CAMPARI, GLAXOSMITHKLINE, HENKEL, HERMES, KLEPIERRE; KERING, MERCK, SAP

LOWEST YTD : MEDIASET

⚠️Downward Signals⚠️

TOTAL : Stock price crossing downward 50,100 & 200d MAV

Bryan Garnier ... Today's comment(s)

Veolia Environnement

RATING : BUY-Top Picks

Fair Value EUR23.5 vs. EUR23

Following yesterday's H1-16 results, we have updated our model on Veolia and adjusted some of our assumptions. While the macro environment remains challenging, notably in France, we have been quite dazzled by the company's solid commercial development over the past semester. This should spur solid growth generation in H2-16 on top of the impressive cost-reduction measures already implemented. This leads us to maintain our Buy rating and slightly increase our FV to EUR23.5 (vs. EUR23). Positive.

UBISOFT	RATING : BUY-	Fair Value EUR34
----------------	----------------------	-------------------------

UBISOFT (Buy, FV EUR34): The "Guillemot family vs. Vivendi" saga goes on. Following the purchase of shares on the market over the last couple of weeks (source: French market regulator AMF) and according to our calculations, the Guillemot family holds 9.23% of UBI's share capital (vs. 8.71% before) and 16.23% of the voting rights (vs. 15.71% before). As a reminder, Vivendi has 22.8% and 20.2% respectively. => **Positive**.

Metro AG	RATING : SELL	Fair Value EUR26 (-9%)
-----------------	----------------------	-------------------------------

Metro has just released Q3 sales and results below expectations at Sales/EBIT level and in line at the NR level. Adjusted EBIT worked out at EUR154m vs EUR190m expected by the consensus, while underlying EPS reached EURO,24 (vs EURO,23). The favorable tax lever (shifting of costs out of Germany, in a bid to boost the domestic operating result at C&C and thus activate the loss carry forward) should not eclipse soft commercial trends... So far, and ahead of conf. call. management has refused to answer the question of whether we can rule out a rights issue in order to address the post spin-off capital structure problem. Stay tuned... Sell maintained. => **Negative**

Fresenius Med. Care	RATING : BUY	Fair Value EUR94 (+15%)
----------------------------	---------------------	--------------------------------

FMC topline results came in line with expectations on the topline (7% CC growth) while outperforming expectations in terms of profitability (EBIT at 14.5% of sales, 40bp ahead of consensus and Net income at USD294m, 4% ahead of consensus) . North America (72% of sales) drove the the performance top to bottom line. On the topline, the region benefitted from 1/ increased DSO and 2/ revenues per tx while EBIT benefitted from 1/ higher volume and 2/ lower cost per tx. FY guidance reiterated.

Fresenius SE	RATING : BUY-Top Picks	Fair Value EUR73 (+9%)
---------------------	-------------------------------	-------------------------------

Fresenius SE reported good set of results which came in-line with estimates. KABI continues to drive performance and notably in NA where EBIT margins are maintained despite a decrease in Organic growth due to high comparison basis. This enables the group to revise 1/ KABI guidance upward with sales and EBIT growth now expected to be up 3-5% and 2/ Goup's net income guidance now expected to growth 11-14%
